Ulcerative colitis is the most common type of inflammatory bowel disease that affects the colon (lining of the large intestine) and rectum. The inflammation produces tiny sores called ulcers. This disease can affect people of any age. The major symptoms of this disease include diarrhea, belly pain/cramps, bleeding from the rectum, also other indications include sudden and unexplained weight loss, loss of appetite, joint pain, eye disease, thickening of the intestinal wall, blood infection (sepsis), kidney stones, and liver disease. The diagnosis of this disease can be carried out by physical examination using tests such as colonoscopy, endoscopy, biopsy, CT scan, and blood test. If ulcerative colitis persists for over eight years or longer, it may lead to colon cancer.
The people having mild symptoms of this disease can be cured by over-the-counter drugs such as Imodium therapy. However, transcription medicine such as steroid medicines and amino salicylates are widely used to treat the condition. In severe cases, the patient may need to undergo surgery to remove the colon, which also helps to prevent colon cancer. The exact cause for ulcerative colitis is unknown, though possible reasons are may be genetic factors, environmental changes, or weakened immune system.
Market players are engaged in receiving approvals from the regulatory authorities, this is expected to drive the growth of the China ulcerative colitis market, over the forecast period. For instance, in 2019, in April, AbbVie announced that the U.S. Food and Drug Administration approved SKYRIZI (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. The drug Risankizumab is the product of a partnership between Boehringer Ingelheim, a research driven pharmaceutical company and AbbVie.
Moreover, in 2019, Janssen Biotech, Inc., a subsidiary of Johnson & Johnson received the U.S. Food and Drug Administration (FDA) approval for STELARA (ustekinumab) for the treatment of adult patients with moderate-to-severe active ulcerative colitis.
Key players are focusing on conducting research and development activities for finding the treatment for the ulcerative colitis and this is expected to increase the growth of the China ulcerative colitis market, over the forecast period. For instance, In August, InDex Pharmaceuticals Holding AB announced positive top line results from the dose optimization study CONDUCT (Cobitolimod as Novel DNA-based Ulcerative Colitis Treatment), which evaluated cobitolimod for the treatment of moderate to severe ulcerative colitis
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
*Browse 49 market data tables and 35 figures on "China Ulcerative Colitis Market” - Forecast to 2030.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.View All Our Clients